FIGHT-MG is a European consortium aiming to shed light on the course of Myasthenia Gravis (MG) disease, but also on the etiological and pathological mechanisms of MG.
Myasthenia Gravis is a rare and heterogeneous neuromuscular disease affecting the neuromuscular junction and leading to abnormal fatigability of various skeletal muscles. The molecular events causing and maintaining MG are still unknown and current treatments do not lead to remission and entail considerable side-effects stressing the need for improved therapies.
The FIGHT-MG will endeavour to:
- Determine factors associated with disease onset and/or affecting the course of disease
- Identify new genetic, epigenetic and environmental risk factors and investigate immunological key molecules associated with MG onset
- Study the pathogenic mechanisms at the neuromuscular junction (molecular changes, morphological changes)
- Establish new diagnostic and monitoring assays (identify pathogenic and protective factors, identify new biomarkers)
- Establish novel therapies (study of new cell-based therapies, non-cell based immunomodulatory therapies, immunoadsorb pathogenic antibodies, target epigenetic regulators)
This multidisciplinary project linking basic researchers with clinical neurologists, SMEs and several European patient associations should favour a translational approach for improved MG management.
|FIGHT-MG is funded by the European Commission within its FP7 specific programme Cooperation; contract no: 242210. Official starting date is 1. December 2009.